Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation
CMV PED Study - A Retrospective Observational Study To Understand The Clinical And Economic Burden Associated With Cytomegalovirus Reactivation and Related Health Outcomes In Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation In Italy
MSD Italia S.r.l.
230 participants
May 9, 2025
OBSERVATIONAL
Conditions
Summary
This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.
Eligibility
Inclusion Criteria3
- Patients from birth to less than 18 years of age (at the moment of the allogeneic HSCT);
- Patients who received allogeneic HSCT between January 2018 and June 2020;
- Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF), if applicable.
Exclusion Criteria1
- Letermovir use at any time
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06916195